CRVI is proud to be working with Optina Diagnostics’ talented team of artificial intelligence experts.
This medical technology (medtech) company is developing a platform that uses a hyperspectral camera to image the retina over a very large number of contiguous spectral bands at very high speed. These hyperspectral retinal images, combined with artificial intelligence, can accurately identify various ocular and neurological pathologies, including Alzheimer’s.
CRVI’s team of experts and researchers is currently in Phase 2 of a project exploring other types of AI algorithms to optimize early detection of Alzheimer’s disease through beta amyloid protein detection.
Like all our clients, we support Optina Diagnostics in finding public funding for applied research to maximize their equity.